High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4

Authors :: Christopher Morehouse
Rajiv Raja
Brandon W. Higgs
Philip Brohawn
Judson Englert
Guozhi Gao
Koustubh Ranade
Sriram Sridhar
Source :: Annals of Oncology. 29:viii19
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
biology
business.industry
Anti pd 1
Hematology
Anti ctla 4
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
PD-L1
biology.protein
Cancer research
Medicine
business

Full Text Access

Tools